UBIQUITIN AND CELLULAR FACTORS IN CORONAVIRUS ASSEMBLY

冠状病毒组装中的泛素和细胞因子

基本信息

  • 批准号:
    7860419
  • 负责人:
  • 金额:
    $ 18.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-06-05 至 2012-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Coronaviruses cause respiratory and gastrointestinal diseases in birds and animals. These RNA viruses are genetically variable and can rapidly evolve to infect humans, sometimes causing severe acute respiratory disease. The coronaviruses are set apart in their assembly and secretion from cells by a strategy involving intracellular virus formation and perhaps novel trafficking routes to the outside environment. Further understanding of these late infection events will identify strategies for therapeutic intervention. We have discovered that a prototype mouse hepatitis coronavirus is inhibited at the assembly and / or secretion stages by very low nontoxic concentrations of a proteasome inhibitor. We hypothesize that the inhibitory mechanism involves ubiquitin depletion from cells, a known effect of proteasome inhibitors, because we discovered that the viral E proteins that are central to virus secretion are ubiquitinated on two lysine residues. Our aims are to determine whether pathogenic human coronaviruses are similarly hypersensitive to proteasome inhibitors and then address whether the ubiquitin conjugation of E proteins is central to coronavirus morphogenesis or expulsion out of cells. Our experiments will specifically evaluate whether the locus of inhibitor and ubiquitin action are at the virus secretion stages and will address the novel hypothesis that ubiquitin modifications direct the trafficking of virus-filled organelles to cell surfaces where the virus cargo is liberated. Our findings will reveal novel cell biological features of vesicle formation and organelle transport and will also inform us about the potential to thwart coronaviruses at late infection stages. PUBLIC HEALTH RELEVANCE: Coronaviruses cause respiratory diseases in humans and domesticated animals and in cases of severe acute respiratory syndrome coronavirus the symptoms can be life threatening. Coronaviruses form in a novel fashion by assembling into organellar vesicles and then expelling from cells when the vesicles fuse to the plasma membrane. As little is known about how this process occurs, the proposal aims to unravel mechanisms of coronavirus assembly and secretion from cells and thereby uncover targets for intervention with this essential infection stage.
描述(由申请人提供):冠状病毒引起鸟类和动物的呼吸道和胃肠道疾病。这些RNA病毒在遗传上是可变的,可以迅速进化感染人类,有时会引起严重的急性呼吸道疾病。冠状病毒在细胞的组装和分泌过程中,通过一种涉及细胞内病毒形成和可能到外部环境的新运输途径的策略而与众不同。进一步了解这些晚期感染事件将确定治疗干预的策略。我们已经发现,一种原型小鼠肝炎冠状病毒在组装和/或分泌阶段被非常低的无毒蛋白酶体抑制剂抑制。我们假设抑制机制涉及细胞中泛素的消耗,这是蛋白酶体抑制剂的已知效应,因为我们发现病毒分泌的中心病毒E蛋白在两个赖氨酸残基上泛素化。我们的目的是确定致病性人类冠状病毒是否对蛋白酶体抑制剂同样过敏,然后确定E蛋白的泛素结合是否对冠状病毒形态发生或排出细胞至关重要。我们的实验将专门评估抑制剂和泛素作用位点是否在病毒分泌阶段,并将解决泛素修饰指导满载病毒的细胞器运输到释放病毒货物的细胞表面的新假设。我们的发现将揭示囊泡形成和细胞器运输的新细胞生物学特征,并将告诉我们在感染后期阻止冠状病毒的潜力。公共卫生相关性:冠状病毒在人类和家畜中引起呼吸道疾病,在严重急性呼吸综合征冠状病毒病例中,症状可能危及生命。冠状病毒以一种新颖的方式形成,通过组装成细胞器囊泡,然后当囊泡与质膜融合时从细胞中排出。由于对这一过程的发生机制知之甚少,该提案旨在揭示冠状病毒组装和细胞分泌的机制,从而揭示干预这一重要感染阶段的目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Thomas Miller Gallagher其他文献

Thomas Miller Gallagher的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Thomas Miller Gallagher', 18)}}的其他基金

Impacts of Adaptive Coronavirus Evolution on Viral Membrane Fusion
冠状病毒适应性进化对病毒膜融合的影响
  • 批准号:
    10727448
  • 财政年份:
    2023
  • 资助金额:
    $ 18.69万
  • 项目类别:
Dissecting the peptide motifs controlling coronavirus infections
剖析控制冠状病毒感染的肽基序
  • 批准号:
    10648391
  • 财政年份:
    2023
  • 资助金额:
    $ 18.69万
  • 项目类别:
Entry and pathogenesis of two human coronaviruses
两种人类冠状病毒的进入和发病机制
  • 批准号:
    8055141
  • 财政年份:
    2011
  • 资助金额:
    $ 18.69万
  • 项目类别:
Entry and Pathogenesis of Coronaviruses
冠状病毒的进入和发病机制
  • 批准号:
    8321679
  • 财政年份:
    2011
  • 资助金额:
    $ 18.69万
  • 项目类别:
UBIQUITIN AND CELLULAR FACTORS IN CORONAVIRUS ASSEMBLY
冠状病毒组装中的泛素和细胞因子
  • 批准号:
    7646778
  • 财政年份:
    2009
  • 资助金额:
    $ 18.69万
  • 项目类别:
UBIQUITIN AND CELLULAR FACTORS IN CORONAVIRUS ASSEMBLY
冠状病毒组装中的泛素和细胞因子
  • 批准号:
    7846495
  • 财政年份:
    2009
  • 资助金额:
    $ 18.69万
  • 项目类别:
Biological Effects of SARS-CoV Spike Polymorphisms
SARS-CoV 刺突多态性的生物学效应
  • 批准号:
    6825526
  • 财政年份:
    2004
  • 资助金额:
    $ 18.69万
  • 项目类别:
Adaptive MERS coronavirus-cell entry pathways and their relevance to virulence and antiviral strategies
适应性 MERS 冠状病毒细胞进入途径及其与毒力和抗病毒策略的相关性
  • 批准号:
    10229391
  • 财政年份:
    2004
  • 资助金额:
    $ 18.69万
  • 项目类别:
Adaptive MERS coronavirus-cell entry pathways and their relevance to virulence and antiviral strategies
适应性 MERS 冠状病毒细胞进入途径及其与毒力和抗病毒策略的相关性
  • 批准号:
    9209899
  • 财政年份:
    2004
  • 资助金额:
    $ 18.69万
  • 项目类别:
MOLECULAR DISSECTION OF THE CORONAVIRUS SPIKE
冠状病毒刺突的分子解剖
  • 批准号:
    2269555
  • 财政年份:
    1993
  • 资助金额:
    $ 18.69万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了